The purpose of this prospective open-label phase II study, is to evaluate the efficacy of
pasireotide twice daily subcutaneous injections for normalizing 24 hour urine free cortisol
in patients with ectopic ACTH-producing tumors as measured by the proportion of patients
achieving normal UFC at the end of the study period.